Supramolecular Assembly‐Enabled Transdermal Therapy of Hypertrophic Scarring Through Concurrent Ferroptosis‐Apoptosis
Source abstract
Abstract
Abstract Hypertrophic scar (HS) remains a major challenge for clinicians due to unsatisfactory therapeutic performance. Although inducing apoptosis of HS fibroblasts (HSFs) has proved to be an effective nonsurgical treatment strategy, potential chemotherapy resistance to apoptosis of HSFs makes the development of new and efficient strategies highly demanding. Herein, a ferroptosis‐apoptosis combined therapeutic strategy for the treatment of HS is developed through supramolecular self‐assembly between cucurbit[7]uril (CB[7]) and two bioactive agents, dihydroartemisinin (DHA) and gold nanoclusters (AuNCs). The resulting self‐assembled supramolecular nanoparticles, named CAD NPs, showed high guest loading efficiency and prominent pH‐responsive degradability in the acidic lysosomes of HSFs. Importantly, both DHA and AuNCs act synergistically to generate excessive reactive oxygen species and lipid peroxidation, leading to mitochondrial damage, and ultimately inducing concurrent ferroptosis and apoptosis on HSFs. Upon further loading into hydrogel microneedles to facilitate their transdermal delivery, these CAD NPs showed superior antiscar therapeutic effects in shortening the treatment span to 3 weeks and improving the HS appearance, as demonstrated at a rabbit ear model of HS. The present supramolecular assembly‐based ferroptosis‐apoptosis strategy provides an innovative guideline for efficiently treating HS as well as other diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Oropharyngeal Anatomy and Pathologies · Connective Tissue Growth Factor Research · Bone and Dental Protein Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Solidification Processing, School of Materials Science and Engineering Northwestern Polytechnical University Xi'an 710072 China
Department of General Surgery the First Affiliated Hospital of Xi'an Medical University Xi'an 710077 China
Funding
National Natural Science Foundation of China · Key Research and Development Projects of Shaanxi Province
References (60)
Show source-provided references
1. 10.1038/s41572-023-00474-x10.1038/s41572-023-00474-x ↗
2. 10.1038/s41467-024-46328-210.1038/s41467-024-46328-2 ↗
3. 10.1016/S0140-6736(16)31406-410.1016/S0140-6736(16)31406-4 ↗
4. 10.1039/D3NR05208G10.1039/D3NR05208G ↗
5. 10.1016/j.ebiom.2020.10271510.1016/j.ebiom.2020.102715 ↗
6. 10.1021/acsnano.1c0782910.1021/acsnano.1c07829 ↗
7. 10.18632/oncotarget.1373410.18632/oncotarget.13734 ↗
8. 10.1002/anie.20230037910.1002/anie.202300379 ↗
9. 10.1038/s41580-024-00703-510.1038/s41580-024-00703-5 ↗
10. 10.1021/acsnano.3c0928610.1021/acsnano.3c09286 ↗
11. 10.1038/s41580-023-00689-610.1038/s41580-023-00689-6 ↗
12. 10.1007/s40820-024-01399-010.1007/s40820-024-01399-0 ↗
13. 10.1016/j.nantod.2024.10224710.1016/j.nantod.2024.102247 ↗
14. 10.1016/j.cclet.2023.10866910.1016/j.cclet.2023.108669 ↗
15. 10.1002/adma.20231331710.1002/adma.202313317 ↗
16. 10.1002/anie.20231815510.1002/anie.202318155 ↗
17. 10.1021/jacs.3c0303110.1021/jacs.3c03031 ↗
18. 10.1002/advs.20230538210.1002/advs.202305382 ↗
19. 10.1007/s40820-024-01438-w10.1007/s40820-024-01438-w ↗
20. 10.1002/adfm.20200727710.1002/adfm.202007277 ↗
21. 10.1016/j.bioactmat.2021.03.02210.1016/j.bioactmat.2021.03.022 ↗
22. 10.1016/j.cclet.2023.10936310.1016/j.cclet.2023.109363 ↗
23. 10.1039/C4NR04227A10.1039/C4NR04227A ↗
24. 10.1016/j.colsurfb.2023.11333610.1016/j.colsurfb.2023.113336 ↗
25. 10.1021/acsami.2c1828910.1021/acsami.2c18289 ↗
26. 10.1021/acsami.2c0505410.1021/acsami.2c05054 ↗
27. 10.1016/S0140-6736(03)15163-X10.1016/S0140-6736(03)15163-X ↗
28. 10.1016/j.nantod.2023.10189610.1016/j.nantod.2023.101896 ↗
29. 10.1002/adma.20230546810.1002/adma.202305468 ↗
30. 10.1021/acs.analchem.3c0505710.1021/acs.analchem.3c05057 ↗
31. 10.1021/acs.analchem.3c0558210.1021/acs.analchem.3c05582 ↗
32. 10.1038/s41467-023-36387-210.1038/s41467-023-36387-2 ↗
33. 10.1002/advs.20240284610.1002/advs.202402846 ↗
34. 10.1002/anie.20201439910.1002/anie.202014399 ↗
35. Leung K. C.‐F. · Chemistry · 2009 · 4 · 364
36. 10.1146/annurev-physchem-040215-11241210.1146/annurev-physchem-040215-112412 ↗
37. 10.1021/ja309990510.1021/ja3099905 ↗
38. 10.1038/239342a010.1038/239342a0 ↗
39. 10.1172/JCI10855610.1172/JCI108556 ↗
40. 10.1038/s41392-020-00428-910.1038/s41392-020-00428-9 ↗
41. 10.1039/C3CC48088G10.1039/C3CC48088G ↗
42. 10.1016/j.jhazmat.2019.12139010.1016/j.jhazmat.2019.121390 ↗
43. 10.1073/pnas.212198711910.1073/pnas.2121987119 ↗
44. 10.1002/adma.20190419710.1002/adma.201904197 ↗
45. 10.1016/j.jconrel.2022.04.04710.1016/j.jconrel.2022.04.047 ↗
46. 10.1021/acsami.1c2286110.1021/acsami.1c22861 ↗
47. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
48. 10.1016/j.jconrel.2024.06.05910.1016/j.jconrel.2024.06.059 ↗
49. 10.1016/S0163-7258(01)00159-010.1016/S0163-7258(01)00159-0 ↗
50. 10.3390/nano1320280210.3390/nano13202802 ↗
51. 10.1002/adfm.20230057510.1002/adfm.202300575 ↗
52. 10.1038/s41598-018-36647-y10.1038/s41598-018-36647-y ↗
53. 10.1016/j.bioactmat.2021.01.01410.1016/j.bioactmat.2021.01.014 ↗
54. 10.1016/S0009-9120(79)80071-510.1016/S0009-9120(79)80071-5 ↗
55. 10.1016/j.apsb.2020.09.00110.1016/j.apsb.2020.09.001 ↗
56. 10.1007/s00403-019-01960-710.1007/s00403-019-01960-7 ↗
57. 10.1016/j.jconrel.2022.01.04310.1016/j.jconrel.2022.01.043 ↗
58. Kong T. Y. · Adv. Funct. Mater. · 2024 · 34
59. 10.1093/burnst/tkad05310.1093/burnst/tkad053 ↗
60. 10.1038/s41374-018-0099-310.1038/s41374-018-0099-3 ↗